{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:22:59Z","timestamp":1791559379638,"version":"4.3.4"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,31]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>IgA nephropathy (IgAN) is a major cause of late graft loss after kidney transplantation, yet evidence for newly approved IgAN-specific therapies in this setting is scarce. We report a young male transplant recipient with biopsy-proven recurrent IgAN 7 years after living-donor transplantation. Treatment with targeted-release budesonide (Nefecon) was associated with a delayed and incomplete antiproteinuric response, clinically relevant systemic glucocorticoid-related adverse effects and progressive graft function decline. After discontinuation of Nefecon, combined therapy with Sparsentan and empagliflozin resulted in sustained albuminuria reduction, stabilization of graft function, improved blood pressure control, and resolution of metabolic complications. This case highlights challenges and opportunities in integrating novel IgAN therapies into post-transplant care.<\/jats:p>","DOI":"10.1093\/ckj\/sfag202","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T11:48:56Z","timestamp":1782301736000},"source":"Crossref","is-referenced-by-count":1,"title":["Differing effects of Nefecon and Sparsentan in a patient with recurrent IgA nephropathy post-kidney transplantation"],"prefix":"10.1093","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5090-2825","authenticated-orcid":false,"given":"Anja S","family":"M\u00fchlfeld","sequence":"first","affiliation":[{"name":"Department of Nephrology, Uniklinik RWTH Aachen , Aachen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Floege","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Uniklinik RWTH Aachen , Aachen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"von\u00a0Stillfried","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Uniklinik RWTH Aachen , Aachen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9921-4284","authenticated-orcid":false,"given":"Peter","family":"Boor","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Uniklinik RWTH Aachen , Aachen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7472-4907","authenticated-orcid":false,"given":"Eleni","family":"Stamellou","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Uniklinik RWTH Aachen , Aachen ,","place":["Germany"]},{"name":"Department of Nephrology, School of Medicine, University of Ioannina , Ioannina ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4048-6351","authenticated-orcid":false,"given":"Rafael","family":"Kramann","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Uniklinik RWTH Aachen , Aachen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8821-1978","authenticated-orcid":false,"given":"Claudia","family":"Seikrit","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Uniklinik RWTH Aachen , Aachen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"2026080708111421300_bib1","doi-asserted-by":"publisher","first-page":"923813","DOI":"10.3389\/fneph.2022.923813","article-title":"Incidence, risk factors, and effect on allograft survival of glomerulonephritis post-transplantation in a United Kingdom population: cohort study","volume":"2","author":"Aguiar","year":"2022","journal-title":"Front Nephrol"},{"key":"2026080708111421300_bib2","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.3389\/fimmu.2019.01332","article-title":"Immunoglobulin A nephropathy. Recurrence after renal transplantation","volume":"10","author":"Moroni","year":"2019","journal-title":"Front Immunol"},{"key":"2026080708111421300_bib3","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1093\/ndt\/gfr664","article-title":"IgA nephropathy recurs early in the graft when assessed by protocol biopsy","volume":"27","author":"Ortiz","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"2026080708111421300_bib4","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.2215\/CJN.00910121","article-title":"Recurrence of IgA nephropathy after kidney transplantation in adults","volume":"16","author":"Uffing","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026080708111421300_bib5","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.kint.2017.03.015","article-title":"Recurrent glomerulonephritis after kidney transplantation: risk factors and allograft outcomes","volume":"92","author":"Allen","year":"2017","journal-title":"Kidney Int"},{"key":"2026080708111421300_bib6","doi-asserted-by":"publisher","first-page":"2472041","DOI":"10.1080\/0886022X.2025.2472041","article-title":"Risk factors for IgA nephropathy recurrence and impact on graft survival in a cohort of kidney transplanted patients","volume":"47","author":"Napoletano","year":"2025","journal-title":"Ren Fail"},{"key":"2026080708111421300_bib7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000530341","article-title":"Current status and perspectives on recurrent IgA nephropathy after kidney transplantation","volume":"147","author":"Kawabe","year":"2023","journal-title":"Nephron"},{"key":"2026080708111421300_bib8","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1111\/ctr.12389","article-title":"The risk of recurrent IgA nephropathy in a steroid-free protocol and other modifying immunosuppression","volume":"28","author":"Von\u00a0Visger","year":"2014","journal-title":"Clin Transplant"},{"key":"2026080708111421300_bib9","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial","volume":"402","author":"Lafayette","year":"2023","journal-title":"Lancet"},{"key":"2026080708111421300_bib10","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","article-title":"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial","volume":"402","author":"Rovin","year":"2023","journal-title":"Lancet"},{"key":"2026080708111421300_bib11","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1056\/NEJMoa2512133","article-title":"Sibeprenlimab in IgA nephropathy\u2014interim analysis of a phase 3 Trial","volume":"394:","author":"Perkovic","year":"2026","journal-title":"N Engl J Med"},{"key":"2026080708111421300_bib12","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa2410316","article-title":"Alternative complement pathway inhibition with iptacopan in IgA nephropathy","volume":"392","author":"Perkovic","year":"2025","journal-title":"N Engl J Med"},{"key":"2026080708111421300_bib13","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1056\/NEJMoa2510198","article-title":"A Phase 3 Trial of atacicept in patients with IgA nephropathy","volume":"394:","author":"Lafayette","year":"2026","journal-title":"N Engl J Med"},{"key":"2026080708111421300_bib14","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1007\/s40620-025-02405-3","article-title":"Treatment of recurrent IgA nephropathy after kidney transplantation with targeted-release budesonide\u2014a case report","volume":"38","author":"Packbiers","year":"2025","journal-title":"J Nephrol"},{"key":"2026080708111421300_bib15","doi-asserted-by":"publisher","first-page":"10693","DOI":"10.3389\/ti.2022.10693","article-title":"Enteric budesonide in transplant and native IgA nephropathy: real-world clinical practice","volume":"35","author":"Lopez-Martinez","year":"2022","journal-title":"Transpl Int"},{"key":"2026080708111421300_bib16","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2025.04.004","article-title":"KDIGO 2025 clinical practice guideline for the management of immunoglobulin A nephropathy (IgAN) and immunoglobulin A vasculitis (IgAV)","volume":"108","author":"Rovin","year":"2025","journal-title":"Kidney Int"},{"key":"2026080708111421300_bib17","doi-asserted-by":"publisher","first-page":"e71474","DOI":"10.1002\/ccr3.71474","article-title":"Treatment of recurrent IgA nephropathy after kidney transplantation: case report and comprehensive literature review","volume":"13","author":"Matarneh","year":"2025","journal-title":"Clin Case Rep"},{"key":"2026080708111421300_bib18","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1097\/FPC.0b013e328364db84","article-title":"PharmGKB summary: cyclosporine and tacrolimus pathways","volume":"23","author":"Barbarino","year":"2013","journal-title":"Pharmacogenet Genomics"},{"key":"2026080708111421300_bib19","doi-asserted-by":"publisher","first-page":"707","DOI":"10.2165\/00002018-200225100-00003","article-title":"Drug interactions with tacrolimus","volume":"25","author":"van\u00a0Gelder","year":"2002","journal-title":"Drug Saf"},{"key":"2026080708111421300_bib20","doi-asserted-by":"publisher","first-page":"sfae394","DOI":"10.1093\/ckj\/sfae394","article-title":"First real-world evidence of sparsentan efficacy in patients with IgA nephropathy treated with SGLT2 inhibitors","volume":"18","author":"Schanz","year":"2025","journal-title":"Clin Kidney J"},{"key":"2026080708111421300_bib21","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"Wheeler","year":"2021","journal-title":"Kidney Int"},{"key":"2026080708111421300_bib22","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1097\/TP.0000000000005496","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists in kidney transplantation: a systematic review and meta-analysis","volume":"110","author":"Lee","year":"2026","journal-title":"Transplantation"},{"key":"2026080708111421300_bib23","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfaf116.0313","article-title":"#1916 Concomitant sparsentan and sodium-glucose cotransporter-2 inhibitors in adults with IgA nephropathy in the phase 2 SPARTACUS trial","volume":"40","author":"Ayoub","year":"2025","journal-title":"Nephrol Dial Transplant"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfag202\/68605440\/sfag202.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/8\/sfag202\/68605440\/sfag202.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/8\/sfag202\/68605440\/sfag202.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T12:11:20Z","timestamp":1786104680000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfag202\/8715473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,7,31]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfag202","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,6,24]]},"article-number":"sfag202"}}